New indication concerns a combination with gemcitabine and cisplatin for the first-line treatment of patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma

Source

RELATED ARTICLESMORE FROM AUTHOR